본문 바로가기
KERD
논문KCI 등재

The Cumulative Effect of Antipsychotic Usage on Mortality in Schizophrenia: A Nationwide Population-based Cohort Study in Korea

Se Jin Park|Subin Park|Gyurin Kim|Soo Jung Rim|Minkyung Jo|Min Geu Lee
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2022.08|Clinical Psychopharmacology and Neuroscience|제20권 제3호|pp. 573-577|DOI 10.9758/cpn.2022.20.3.573

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

SchizophreniaMortalitySouth KoreaAntipsychotics

초록

Objective: To investigate the cumulative effect of antipsychotics at different dosages on mortality in patients with schizophrenia. Methods: We analyzed data from the Korean National Health Insurance System−National Sample Cohort covering the 2002−2013 period. We used Cox regression analysis to calculate hazard ratios for mortality risks according to cumulative antipsychotic exposure levels (low, moderate, and high). Results: Our analyses revealed no significant association between antipsychotic exposure and mortality (either all-cause or cause-specific) in patients with schizophrenia. Conclusion: Our results imply that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic usage.

Abstract

Objective: To investigate the cumulative effect of antipsychotics at different dosages on mortality in patients with schizophrenia. Methods: We analyzed data from the Korean National Health Insurance System−National Sample Cohort covering the 2002−2013 period. We used Cox regression analysis to calculate hazard ratios for mortality risks according to cumulative antipsychotic exposure levels (low, moderate, and high). Results: Our analyses revealed no significant association between antipsychotic exposure and mortality (either all-cause or cause-specific) in patients with schizophrenia. Conclusion: Our results imply that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic usage.

참고문헌 (25)

  1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
  2. Simeone JC, "An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013 : a systematic literature review", BMC Psychiatry, 15, pp.193~ (2015)
  3. Chong HY, "Global economic burden of schizophrenia : a systematic review", Neuropsychiatr Dis Treat, 12, pp.357~373 (2016)
  4. He H, "Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels : results from the Global Burden of Disease Study 2017", Epidemiol Psychiatr Sci, 29, pp.e91~ (2020)
  5. De Hert M, "Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association(EPA), supported by the European Association for the Study of Diabetes(EASD)and the European Society of Cardiology(ESC)", Eur Psychiatry, 24, pp.412~424 (2009)
  6. Olfson M, "Premature mortality among adults with schizophrenia in the United States", JAMA Psychiatry, 72, pp.1172~1181 (2015)
  7. Ko YS, "Higher mortality and years of potential life lost of suicide in patients with schizophrenia", Psychiatry Res, 270, pp.531~537 (2018)
  8. Galletly CA, "Premature death in schizophrenia : bridging the gap", Lancet Psychiatry, 4, pp.263~265 (2017)
  9. Weinmann S, "Influence of antipsychotics on mortality in schizophrenia : systematic review", Schizophr Res, 113, pp.1~11 (2009)
  10. Crump C, "Comorbidities and mortality in persons with schizophrenia : a Swedish national cohort study", Am J Psychiatry, 170, pp.324~333 (2013)
  11. Cullen BA, "Guideline-concordant antipsychotic use and mortality in schizophrenia", Schizophr Bull, 39, pp.1159~1168 (2013)
  12. Baandrup L, "Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia : a population-based nested case-control study", J Clin Psychiatry, 71, pp.103~108 (2010)
  13. Tiihonen J, "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
  14. Tiihonen J, "11-year follow-up of mortality in patients with schizophrenia : a population-based cohort study(FIN11study)", Lancet, 374, pp.620~627 (2009)
  15. Tiihonen J, "Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia : an observational follow-up study", Am J Psychiatry, 173, pp.600~606 (2016)
  16. Torniainen M, "Antipsychotic treatment and mortality in schizophrenia", Schizophr Bull, 41, pp.656~663 (2015)
  17. Sundararajan V, "New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality", J Clin Epidemiol, 57, pp.1288~1294 (2004)
  18. Taipale H, "20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62, 250 patients with schizophrenia(FIN20)", World Psychiatry, 19, pp.61~68 (2020)
  19. Vermeulen JM, "Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years", Schizophr Bull, 45, pp.315~329 (2019)
  20. Taipale H, "Antipsychotics and mortality in a nationwide cohort of 29, 823 patients with schizophrenia", Schizophr Res, 197, pp.274~280 (2018)
  21. Huang CY, "Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia", JAMA Netw Open, 4, pp.e218810~ (2021)
  22. Lahti M, "Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia", Psychol Med, 42, pp.2275~2285 (2012)
  23. Laursen TM, "Excess early mortality in schizophrenia", Annu Rev Clin Psychol, 10, pp.425~448 (2014)
  24. Oh J, "Decreased cardiovascular death in schizophrenia patients treated with antipsychotics : a Korean national cohort study", Schizophr Res, 228, pp.417~424 (2021)
  25. Brown S, "Causes of the excess mortality of schizophrenia", Br J Psychiatry, 177, pp.212~217 (2000)

관련 논문AI추천

Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study김하린, 송민호, 안수진, 이중선, 조영탁, 주성우, 최영재대한조현병학회 · 대한조현병학회지2021 · 제24권 제2호Adherence to Antipsychotic Drugs by Medication Possession Ratio for Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A Retrospective Cohort StudyJee Hoon Sohn, Jin Yong Lee, Jungmee Kim, Sung Joon Cho대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제3호한국 조현병 환자에서 벤조다이아제핀의 사용 : 건강보험심사평가원 자료 분석이상욱, 최성구, 황태연대한신경정신의학회 · 신경정신의학2017 · 제56권 제4호Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study권준수, 김대호, 김성완, 김재진, 김종훈, 남희정, 박일호, 안석균, 오홍석, 원승희, 유승형, 이강욱, 이규영, 이승환, 이유상, 이중서, 이중선, 주연호, 홍경수대한신경정신의학회 · PSYCHIATRY INVESTIGATION2017 · 제14권 제1호Antipsychotic Effects of Quetiapine in Naturalistic Long Term Follow Up Study김도훈, 김창윤, 안중호, 유소영, 이상혁, 이중선, 임세원, 임원정, 조인희, Dong-Geun Lee, Dong-Hwan Cho, Hae-Kyung Jung, Il-Kyung Jung, Jong-Jin Kim, Tae-Young Kim대한신경정신의학회 · PSYCHIATRY INVESTIGATION2010 · 제7권 제2호조현병을 처음 진단받은 환자들의 초기 투약 순응도에 따른 발병 1년 후 임상 결과: 국민건강보험공단 자료에 기반한 후향적 코호트 연구김선민, 안수진, 이중선, 주성우, 최영재, 최우혁대한조현병학회 · 대한조현병학회지2023 · 제26권 제1호

이 간행물의 다른 논문 (19건)

Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical PredictorsStefano Damiani, Ilaria Casolaro, Chiara Amendola, Calogero Crapanzanopp. 403-414Alterations of Power Spectral Density in Salience Network during Thought-action Fusion Induction Paradigm in Obsessive-compulsive DisorderHeajung Choi, Tae Yang Jang, Sang Won Lee, Eunji Kim, Seungho Kim, 송희진, 이승재, Yongmin Chang, Moon Jung Hwangpp. 415-426Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical SettingWilson Tan, Paul Bergmans, Ahmad Hatim Sulaiman, Young-Chul Chung, Yen Kuang Yangpp. 427-439Apnea-hypopnea Index is Correlated with Pulse Rate in Patients with Sleep-related Breathing Disorder without Hypertension, Cardiovascular Disease, or Diabetes MellitusKwang-Pil Ko, 김지언, 강승걸, 신승헌, Seo-Eun Cho, 문정근, Jae Hyoung Park, Jae-Kean Ryupp. 440-449Machine-Learning for Prescription Patterns: Random Forest in the Prediction of Dose and Number of Antipsychotics Prescribed to People with SchizophreniaMattia Marchi, Giacomo Galli, Gianluca Fiore, Andrew Mackinnon, Giorgio Mattei, Fabrizio Starace, Gian M. Galeazzipp. 450-461
원문 보기